The costs and cost-effectiveness of an integrated sepsis treatment protocol

Context:Sepsis is associated with high mortality and treatment costs. International guidelines recommend the implementation of integrated sepsis protocols; however, the true cost and cost-effectiveness of these are unknown. Objective:To assess the cost-effectiveness of an integrated sepsis protocol, as compared with conventional care. Design:Prospective cohort study of consecutive patients presenting with septic shock and enrolled in the institution's integrated sepsis protocol. Clinical and economic outcomes were compared with a historical control cohort. Setting:Beth Israel Deaconess Medical Center. Patients:Overall, 79 patients presenting to the emergency department with septic shock in the treatment cohort and 51 patients in the control group. Interventions:An integrated sepsis treatment protocol incorporating empirical antibiotics, early goal-directed therapy, intensive insulin therapy, lung-protective ventilation, and consideration for drotrecogin alfa and steroid therapy. Main Outcome Measures:In-hospital treatment costs were collected using the hospital's detailed accounting system. The cost-effectiveness analysis was performed from the perspective of the healthcare system using a lifetime horizon. The primary end point for the cost-effectiveness analysis was the incremental cost per quality-adjusted life year gained. Results:Mortality in the treatment group was 20.3% vs. 29.4% in the control group (p = .23). Implementing an integrated sepsis protocol resulted in a mean increase in cost of ∼$8,800 per patient, largely driven by increased intensive care unit length of stay. Life expectancy and quality-adjusted life years were higher in the treatment group; 0.78 and 0.54, respectively. The protocol was associated with an incremental cost of $11,274 per life-year saved and a cost of $16,309 per quality-adjusted life year gained. Conclusions:In patients with septic shock, an integrated sepsis protocol, although not cost-saving, appears to be cost-effective and compares very favorably to other commonly delivered acute care interventions.

[1]  Nathan Shapiro,et al.  When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature* , 2006, Critical care medicine.

[2]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[3]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[4]  J. Vincent,et al.  Has the mortality of septic shock changed with time. , 1998, Critical care medicine.

[5]  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock , 2003, Current infectious disease reports.

[6]  G. Sanders,et al.  Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. , 2003, Journal of critical care.

[7]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[8]  D C Angus,et al.  Quality-adjusted survival in the first year after the acute respiratory distress syndrome. , 2001, American journal of respiratory and critical care medicine.

[9]  Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. , 1997, JAMA.

[10]  D. Angus,et al.  Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom* , 2005, Anaesthesia.

[11]  E. Rivers,et al.  Early goal-directed therapy prevents organ failure and mortality in severe sepsis and septic shock , 2003 .

[12]  A. Rosen,et al.  PMC14 PREVAILING JUDGMENTS ABOUT SOCIETY'S WILLINGNESS TO PAY FORA QALY: DO THEY VARY BY COUNTRY? HAVE THEY CHANGED OVERTIME? , 2006 .

[13]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[14]  Mark S. Roberts,et al.  Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. , 2002, American journal of respiratory and critical care medicine.

[15]  D. Angus,et al.  Economic evaluation of new therapies in critical illness , 2003, Critical care medicine.

[16]  M Schetz,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[17]  E. Arias,et al.  United States life tables, 2002. , 2004, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[18]  Gary Garber,et al.  The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000) , 2001 .

[19]  Scott T. Micek,et al.  Before–after study of a standardized hospital order set for the management of septic shock* , 2006, Critical care medicine.

[20]  David W Bates,et al.  Mortality in Emergency Department Sepsis (MEDS) score: A prospectively derived and validated clinical prediction rule* , 2003, Critical care medicine.

[21]  R. Willke,et al.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  C. Formica,et al.  PID7: OBSERVATIONAL EVALUATION OF HEALTH STATE UTILITIES AMONG A COHORT OF SEPSIS PATIENTS , 2001 .

[23]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[24]  Margaret M Parker,et al.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.

[25]  Daniel Talmor,et al.  A blueprint for a sepsis protocol. , 2005, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[26]  Shu-Min Lin,et al.  A MODIFIED GOAL-DIRECTED PROTOCOL IMPROVES CLINICAL OUTCOMES IN INTENSIVE CARE UNIT PATIENTS WITH SEPTIC SHOCK: A RANDOMIZED CONTROLLED TRIAL , 2006, Shock.

[27]  M. Kollef,et al.  Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin* , 2004, Critical care medicine.

[28]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[29]  F. Gao,et al.  The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study , 2005, Critical care.

[30]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[31]  Cam Donaldson,et al.  An economic evaluation of activated protein C treatment for severe sepsis. , 2002, The New England journal of medicine.

[32]  Daniel Talmor,et al.  Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol* , 2006, Critical care medicine.

[33]  G. Clermont,et al.  Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis* , 2003, Critical care medicine.

[34]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[35]  W. Aird,et al.  Targeting the Hprt locus in mice reveals differential regulation of Tie2 gene expression in the endothelium. , 2000, Physiological genomics.

[36]  P. Peduzzi,et al.  Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. , 1997, JAMA.